Aberrant microRNA expression in tumor mycosis fungoides.
Herein, miRNA candidates relevant to mycosis fungoides were investigated to provide data on the molecular mechanisms underlying the pathogenesis of the disease. The miRNA expression profile of skin biopsies from patients with tumor stage MF (tMF) and normal donors was compared using miRNA microarrays. Overall, 154 miRNAs were found differentially expressed between tMF and the control cohort with the majority of them being up-regulated (57 %). Among the upregulated miRNAs, miR-3177, miR-514b-3p, miR-1267, and miR-1282 were exclusively detected in 70 % of tMF. Additional upregulated miRNAs included miR-34a, miR-29a, let-7a*, and miR-210, while miR-200c* was identified among the downregulated ones. Quantitative real-time polymerase chain reaction was used to further investigate the expression profiles of miR-34a and miR-29a and validated the overexpression of miR-34a. Enrichment studies revealed that the target genes of the differentially expressed miRNAs were important in several cancer-related signaling pathways. The overlapping relationship of the target genes among tMF, Sezary syndrome, and atopic dermatitis revealed several common and disease-specific genes. Collectively, our study modulated miR-34a as a candidate oncogenic molecule and miR-29a as a putative tumor suppressor highlighting their promising potential in the molecular pathogenesis of tMF.
1st Department of Dermatology and Cutaneous Lymphoma Clinic, Andreas Sygros Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.|2nd Departments of Dermatology and Cutaneous Lymphoma clinic, Attikon Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
E
E
Papadavid
University Research Institute for the Study and Treatment of Childhood Genetic and Malignant Diseases, National and Kapodistrian University of Athens Medical School, Athens, Greece.|Department of Medical Genetics, National and Kapodistrian University of Athens Medical School, Athens, Greece.
M
M
Braoudaki
Center of Systems Biology, Biomedical Research Foundation, Academy of Athens, Soranou Ephessiou 4, 115 27, Athens, Greece.
M
M
Bourdakou
Department of Medical Genetics, National and Kapodistrian University of Athens Medical School, Athens, Greece.
A
A
Lykoudi
1st Department of Dermatology and Cutaneous Lymphoma Clinic, Andreas Sygros Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
V
V
Nikolaou
Department of Medical Genetics, National and Kapodistrian University of Athens Medical School, Athens, Greece.
G
G
Tounta
1st Department of Dermatology and Cutaneous Lymphoma Clinic, Andreas Sygros Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
A
A
Ekonomidi
Center of Systems Biology, Biomedical Research Foundation, Academy of Athens, Soranou Ephessiou 4, 115 27, Athens, Greece.
E
E
Athanasiadis
Center of Systems Biology, Biomedical Research Foundation, Academy of Athens, Soranou Ephessiou 4, 115 27, Athens, Greece.
G
G
Spyrou
1st Department of Dermatology and Cutaneous Lymphoma Clinic, Andreas Sygros Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
C
C
Antoniou
Department of Medical Genetics, National and Kapodistrian University of Athens Medical School, Athens, Greece.
S
S
Kitsiou-Tzeli
2nd Departments of Dermatology and Cutaneous Lymphoma clinic, Attikon Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
D
D
Rigopoulos
Department of Medical Genetics, National and Kapodistrian University of Athens Medical School, Athens, Greece. akolial@med.uoa.gr.
A
A
Kolialexi
D014408:Biomarkers, Tumor / Q000235:genetics*; D016022:Case-Control Studies; D016000:Cluster Analysis; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D009182:Mycosis Fungoides / Q000235:genetics* / Q000473:pathology; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012878:Skin Neoplasms / Q000235:genetics* / Q000473:pathology
D014408:Biomarkers, Tumor; D035683:MicroRNAs
Pathway analysis; T-cell lymphomas; miRNA microarrays; qRT-PCR